Curis
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Curis sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Curis: 12 sponsored US clinical trials, 2 recruiting.
Curis sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NUT Midline Carcinoma, with 1 trials.
Top-decile sponsor footprint
Curis ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
12 total, page 1 of 1
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
NCT04475523
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
NCT02674750
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
NCT02812875
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
NCT02307240
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
NCT01908413
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
NCT01742988
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
NCT01702285
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
NCT01384799
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
NCT01171924
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
NCT00728793
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Curis pipeline
2 recruiting of 12 indexed (17% open); 8 completed (67%).
Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: NUT Midline Carcinoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Curis: open-pipeline peers nationwide
Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Curis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Curis page
12 registered trials is a research-attention snapshot, not an endorsement of Curis or any single study.
- 2 of Curis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NUT Midline Carcinoma is the condition Curis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NUT Midline Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Curis pipeline card: 12 registered trials from official public datasets.Report a data error.